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Summary
 
In many chronic inflammatory disorders, glucocorticoid (GC) insensitivity is a challenging clin-
ical problem associated with life-threatening disease progression. The molecular basis of GC in-
sensitivity, however, is unknown. Alternative splicing of the GC receptor (R) pre–messenger
RNA generates a second GCR, termed GCR-
 
b
 
, which does not bind GCs but antagonizes
the transactivating activity of the classic GCR, termed GCR-
 
a
 
. In the current study, we dem-
onstrate that GC-insensitive asthma is associated with a significantly higher number of GCR-
 
b
 
–immunoreactive cells in peripheral blood than GC-sensitive asthmatics or normal controls.
Furthermore, we show that patients with GC-insensitive asthma have cytokine-induced abnor-
malities in the DNA binding capability of the GCR. These abnormalities can be reproduced by
transfection of cell lines with the GCR-
 
b
 
 gene resulting in significant reduction of their GCR-
 
a
 
DNA binding capacity. We conclude that increased expression of GCR-
 
b
 
 is cytokine induc-
ible and may account for GC insensitivity in this common inflammatory condition.
 
G
 
lucocorticoid (GC)
 
1
 
 insensitivity is increasingly being
recognized in the management of chronic inflamma-
tory diseases such as asthma, rheumatoid arthritis, systemic
lupus erythematosus, and transplantation rejection. It poses
a major clinical challenge as GC therapy is the cornerstone
of antiinflammatory therapy. Delineation of the molecular
basis for GC insensitivity is critical for the development of
new treatment approaches for this group of refractory pa-
tients, and may provide new insights into the pathogenesis
of chronic inflammation. GC insensitivity has been most
extensively studied in chronic asthma, as the failure here to
respond to GCs is more readily demonstrated than in other
inflammatory diseases (1). Previous studies on PBMCs from
patients with GC-insensitive asthma have revealed that GCs
fail to inhibit their mitogen-induced T cell proliferation
and cytokine secretion in vitro (2, 3). In addition, T cells
from peripheral blood of GC-insensitive asthmatics, but
not GC-sensitive asthmatics, are persistently activated de-
spite high doses of GC therapy (4).
GCs act by binding to a cytoplasmic glucocorticoid re-
ceptor (GCR) which then translocates to the nucleus as a
transcription factor (5). Recently, we found that the ma-
jority of patients with GC-insensitive asthma have a revers-
ible defect in PBMC GCR ligand binding affinity which
can be sustained in vitro by the addition of IL-2 and IL-4
but not the individual cytokines (6). Furthermore, in vitro
incubation of normal peripheral blood T cells with the com-
bination of IL-2 and IL-4 reduces their GCR ligand bind-
ing affinity to the level seen in GC-insensitive asthma (7).
Bronchoscopy studies indicate that airway T cells of GC-
insensitive, as compared to GC-sensitive, asthma have sig-
nificantly higher levels of IL-2 and IL-4 gene expression
(8). Overall these data support the concept that GC-insen-
sitive asthma results from high level expression of IL-2 and
IL-4 which leads to reduced GCR binding affinity and de-
creased T cell responsiveness to GCs.
Independent studies by other investigators have recently
reported that PBMCs from patients with GC-insensitive
asthma have a decreased ability of their GCRs to bind its
specific DNA recognition sequence (glucocorticoid response
elements, i.e., GRE; reference 9). In the current study, we
extended our analysis of PBMCs from GC-insensitive asth-
matics to demonstrate that our patients previously found to
 
1
 
Abbreviations used in this paper:
 
 EMSA, electromobility shift assay; FEV
 
1
 
,
forced expiratory volume in one second; GC, glucocorticoid; GRE, glu-
corticoid response element; mRNA, messenger RNA.
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have abnormally low GCR ligand binding affinity also have a
GCR DNA binding defect. More importantly, we report
for the first time that the combined GCR ligand and DNA
binding defect in GC-insensitive asthma is due to cyto-
kine-induced expression of GCR-
 
b
 
, a newly identified in-
hibitor of GC action.
 
Materials and Methods
 
Patient Selection.
 
Informed consent was obtained from all pa-
tients before their entry into this study. Patients with a diagnosis
of asthma, based on The American Thoracic Society criteria (10),
were selected for evaluation. They were included if they had a
morning prebronchodilator FEV
 
1
 
 
 
,
 
70% of predicted values and a
 
>
 
15% increase in forced expiratory volume in one second (FEV
 
1
 
)
after two inhalations of albuterol (90 
 
m
 
g/actuation). Patients were
excluded if they had evidence for other types of lung disease. Pa-
tients were classified as GC-sensitive or GC-insensitive based on
their prebronchodilator morning FEV
 
1
 
 and response to a course
of oral prednisone (6). Asthmatic patients were defined as GC-
insensitive if they failed to improve their morning prebronchodi-
lator FEV
 
1
 
 by 
 
>
 
15% after a 1-wk course of prednisone at a
minimum oral dose of 40 mg/day. Patients were classified as GC-
sensitive if they had an increase in baseline FEV
 
1
 
 of 30% or
greater.
 
Cell Cultures.
 
Peripheral blood was collected in heparinized
syringes and PBMCs isolated by Ficoll-Paque
 
Ò
 
 (Pharmacia, Pis-
cataway, NJ) gradient centrifugation. PBMCs from normal donors
and GC-insensitive asthma patients were isolated and resuspended
at a concentration of 10
 
6
 
 cells/ml in RPMI 1640 medium (GIBCO
BRL, Gaithersburg, MD) containing 10% fetal calf serum (Hy-
Clone Labs, Logan, UT). Cells were incubated in the absence
and presence of IL-2 (50 U/ml; Chiron Corp., Emeryville, CA)
and/or IL-4 (50 U/ml; Schering-Plough Research Institute,
Bloomfield, NJ) for 48 h at 37
 
8
 
C in 5% CO
 
2
 
 before analysis.
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts were pre-
pared from PBMCs as previously described in reference 11. GCR
DNA binding was analyzed by electrophoretic mobility shift assay
(EMSA) using a 30-bp double-stranded oligonucleotide com-
posed of two complementary strands: 5
 
9
 
-TCGACTGATTA-
CAAACTGTTCTTGCTACT-3
 
9
 
 and 5
 
9
 
-AGTAGCAAGAA-
CAGTTTGTAATCAGTCGA-3
 
9
 
. The oligonucleotide probe was
end labeled with 
 
32
 
P-ATP and polynucleotide kinase. The labeled
probe (50,000 cpm/reaction) was incubated with PBMC nuclear
extract protein (
 
z
 
5 
 
m
 
g) in 20-
 
m
 
l reactions containing 20 mM
Hepes 7.9, 10% glycerol, 3 mM MgCl
 
2
 
, 1 mM dithiothreitol, 0.5
mM EDTA, and 1 
 
m
 
g poly dI:dC for 30 min on ice. Some re-
actions also contained other oligonucleotides and antibodies to
c-Jun or NF-
 
k
 
B (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
as indicated for specificity controls. Affinity-purified rabbit anti–
human GCR (Affinity BioReagents, Neshanic Station, NJ) was
also used for supershift experiments. Reactions were then sepa-
rated on 6% nondenaturing polyacrylamide gels containing 0.25 
 
3
 
tris-buric acid EDTA buffer at 250 V until the free oligonucleotide
probe had migrated to the bottom of the gel. Gels were then ex-
posed to Kodak XAR5 film (Rochester, NY) and GCR DNA
binding was quantitated by densitometry of the developed films.
Saturation binding assays for GCR DNA binding were per-
formed as described above. The reactions contained 
 
z
 
5 
 
m
 
g of
PBMC nuclear extract protein and from 0.1 to 100 ng of labeled
glutocorticoid response element (GRE) probe. After the reactions
were resolved on polyacrylamide gels, levels of bound and free
probe in each reaction were determined by densitometry of auto-
radiograms. Dissociation constants (Kds) for GCR DNA binding
were derived from the slope of curves of saturation binding data
plotted by the method of Scatchard (12).
 
Western Blot Analysis of GCR.
 
PBMC nuclear extracts were
prepared as described above. After correcting for protein concen-
trations, 
 
z
 
50 
 
m
 
g of nuclear extract protein was resolved on 10%
polyacrylamide–SDS gels and transferred to nitrocellulose. The
nitrocellulose blots were blocked with phosphate-buffered saline
containing 5% dry milk and 0.1% Tween 20, and then treated
with affinity-purified rabbit anti–human GCR (Affinity Bio Re-
agents, Neshanic Station, NJ). The blots were washed and subse-
quently treated with goat anti–rabbit IgG conjugated to alkaline
phosphatase. After the blots were washed, specific immune com-
plexes were visualized with bromo-chloro-indoyl-phosphate and
nitroblue tetrazolium.
 
Immunohistochemistry Staining.
 
GCR-
 
b
 
 immunoreactivity was
detected in acetone/methanol–fixed cytospins of PBMCs by the
use of a GCR-
 
b
 
–specific polyclonal rabbit antibody raised against
human GCR-
 
b
 
. This antibody has previously been shown to be
specific for GCR-
 
b
 
 (13), and has no cross-reactivity against
GCR-
 
a
 
. The specificity of the antibody–antigen reaction for im-
munocytochemistry was tested by preabsorption of the antibody
with excess purified GCR-
 
b
 
 antigen which resulted in a loss of
reactivity (data not shown). The reaction was visualized using the
avidin-biotin-peroxidase complex method as previously described
(14). For negative control preparations, the primary antibody was
replaced by either nonspecific rabbit immunoglobulin or Tris-
buffered saline. The percentage of cells positive for GCR-
 
b
 
 in
each preparation were enumerated by a blinded assessor counting
a minimum of 1,000 total cells.
 
Statistical Analysis.
 
Group means were expressed as the arith-
metic mean 
 
6
 
 standard error of the mean. Statistical comparisons be-
tween groups used the Student’s 
 
t
 
 test (nonpaired) with the 
 
P
 
 
 
,
 
0.05
representing a significant result.
Figure 1. Specificity of electrophoretic mobility shift blot for GCR–
GRE interactions using nuclear extracts from a normal subject. The spe-
cific monomeric and dimeric GCR–GRE retarded bands are indicated by
arrows. The effect of dexamethasone (1 mM) on the density of the GCR–
GRE band is shown at 60 min. Specificity is shown by the inhibitory ef-
fect of 100-fold excess of unlabeled oligonucleotide and anti-GCR antibody
on GCR–GRE binding. 
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Results
 
An EMSA was used to measure the interaction between
GCR and its specific DNA recognition sequence or GRE.
The first step in these studies was to confirm that the DNA
binding activity observed in our EMSAs was due to GCR
DNA binding. As shown in Fig. 1, two retarded bands,
corresponding to monomeric and dimeric GCRs, were ob-
served in EMSAs performed with a 30-bp oligonucleotide
containing the consensus GRE. Although these two bands
were observed in reactions performed with nuclear extracts
from untreated cells, their intensity was much higher in re-
actions containing extracts from dexamethasone-treated cells.
A 100-fold excess of cold nonspecific oligonucleotide con-
taining the consensus CCAAT/enhancer binding protein
binding sequence had no effect on the DNA binding activity,
but excess cold GRE oligonucleotide completely inhibited
formation of the two retarded bands. Likewise, antibodies to
the GCR completely blocked complex formation, whereas
antibodies to other transcription factors had no effect on
DNA binding. The ability of dexamethasone to enhance
complex formation and the ability of GCR specific anti-
bodies and oligonucleotides to inhibit their formation
clearly indicates that the DNA binding activity observed in
these reactions is due to the GCR.
We next compared GCR DNA binding in nuclear ex-
tracts from 10 normal subjects, 6 GC-sensitive, and 8 GC-
insensitive individuals (Fig. 2). In these experiments, PBMCs
were treated with dexamethasone to translocate the GCRs
to the nucleus. We found significant levels of GCR DNA
binding in nuclear extracts from normal and GC-sensitive
individuals (Fig. 2, 
 
A
 
). When quantitated by densitometry of
the autoradiographs, no significant difference in GCR DNA
binding levels was noted between these two populations (Fig.
2, 
 
C
 
). In contrast, nuclear extracts from GC-insensitive pa-
tients demonstrated significantly lower (
 
P
 
 
 
,
 
0.001) levels of
GCR DNA binding than normals or GC-sensitive individ-
uals (Fig. 2, 
 
A
 
 and 
 
C
 
). The decreased binding in these sam-
ples was not due to decreased GCR protein levels, as
Western blot analysis of the nuclear extracts from normal,
GC-sensitive, and GC-insensitive subjects revealed compa-
rable levels of GCR protein (Fig. 2, 
 
B
 
).
The low levels of GCR DNA binding in the GC-insen-
sitive samples appears to be due to decreased GCR DNA
binding affinity as compared to binding in normal and GC-
sensitive individuals determined by saturation binding ex-
periments. Fig. 3 shows a Scatchard plot of a representative
saturation binding experiment comparing GCR DNA bind-
ing in a nuclear extract from a GC-sensitive subject to
binding in a nuclear extract from a GC-sensitive patient.
The slope of the curve derived from the GC-sensitive pa-
tient indicates a 
 
K
 
d
 
 of 
 
z
 
10
 
2
 
9
 
 M, whereas the curve ob-
tained from the GC-insensitive patient indicated a lower
affinity interaction with a 
 
K
 
d
 
 of 10
 
2
 
8
 
 M.
We next tested the effect of combination IL-2 and IL-4
on GCR DNA binding in nuclear extracts from GC-insen-
sitive individuals. For these experiments, nuclear extracts
Figure 2. GCR binding to
specific consensus double-
stranded DNA binding se-
quences for GRE in nuclear ex-
tracts obtained from PBMCs
from GC-insensitive (n 5 8),
GC-sensitive asthmatics (n 5 6),
and normal subjects (n 5 10).
(A) A representative EMSA for
GCR–GRE interactions using
freshly isolated nuclear extracts
from PBMCs of three normal
subjects, three GC-sensitive,
and four GC-insensitive asth-
matics. (B) A Western blot of the
same PBMC nuclear extracts
probed with affinity-purified
rabbit anti–human GCR (Affin-
ity BioReagents, Neshanic Sta-
tion, NJ). Equal amounts of nu-
clear extract protein were assayed in each lane of A and B. (C) The average, relative GCR DNA binding in nuclear extracts from PBMCs of normal,
GC-sensitive, and GC-insensitive subjects determined by densitometric quantitation of multiple experiments. Levels are shown relative to the maximum
binding observed in normal subjects.
Figure 3. Saturation binding
analysis of GCR DNA binding
affinity in nuclear extracts from
GC-sensitive and GC-insensitive
patients. Nuclear extracts were
prepared from PBMCs of a GC-
sensitive and a GC-insensitive
asthmatic. Approximately 5 mg
of nuclear extract protein from
each subject was incubated in re-
actions with concentrations of
32P-labeled GRE probe from 0.1
to 100 ng. The reactions were
separated on polyacrylamide gels
and exposed to film. The result-
ing autoradiograms were subjected to densitometry to quantitate levels of
bound and free probe. Both shifted bands were included in the bound
probe levels. The figure shows the binding data plotted by the method of
Scatchard. 
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were prepared from freshly isolated PBMCs or from cells
incubated in culture for 48 h in the presence or absence of
IL-2 and IL-4. Fig. 4 shows the results of four experiments
using PBMCs from four GC-insensitive patients. As ex-
pected, very little GCR DNA binding was present in
freshly isolated PBMCs from any of the patients. However,
after 48 h in the absence of IL-2 and IL-4, there was a sig-
nificant (
 
P
 
 
 
,
 
0.01) increase in GCR DNA binding in all
four samples. Interestingly, this increase in GCR DNA
binding was blocked or inhibited in the cells cultured in
IL-2 and IL-4. These data suggest that the combination of
these two cytokines plays a significant role in triggering and
maintaining the GCR DNA binding defect.
The actual mechanisms by which cytokines or immune
activation might induce a decrease in GCR-GRE binding
are unknown. Cloning of the human GCR cDNA and gene
revealed that alternative splicing of the GCR pre–messen-
ger RNA (mRNA) gives rise to an additional homologous
mRNA and protein isoform, termed GCR-
 
b
 
, that is dis-
tinct from the ligand-activated classical GCR, GCR-
 
a
 
. Both
mRNAs contain the first eight exons of the GCR gene (15).
The remainder is derived by alternative splicing of the nu-
cleotide sequence encoded by the last exon of the GCR
gene, corresponding to either exon 9
 
a
 
 or 9
 
b
 
. The two
protein isoforms have the same first 727 NH2-terminal
amino acids. GCR-b differs from GCR-a only in its
COOH terminus with replacement of the last 50 amino
acids of GCR-a with a unique 15 amino acid sequence.
These differences render GCR-b unable to bind GC hor-
mones, thereby antagonizing the transactivating activity of
the classic GCR-a molecule (16, 17). Recent studies also
indicate that, in the presence of GC, GCR-b heterodimer-
izes with ligand-bound GCR-a and translocates into the
nucleus where it acts as a dominant negative inhibitor of
the classic GCR (13).
To determine whether overexpression of GCR-b might
also result in reduced GCR DNA binding activity, HepG2
cell lines were transfected with increasing amounts of a
plasmid, pRSV–GCR-b, from which the full-length GCR-b
protein was expressed. The cells were cotransfected with
the plasmid, pHook-1, which allowed us to separate the
transfected cells from untransfected cells by using the Cap-
ture-Tec System (Invitrogen, Carlsbad, CA). Nuclear ex-
tracts from the transfected, GCR-b–expressing cells were
subjected to EMSA using the labeled GRE probe. As shown
in Fig. 5, the introduction of GCR-b into HepG2 cells in-
hibits GCR DNA binding activity in nuclear extracts. The
ability of GCR-b to block GCR DNA binding exhibited
concentration dependence as very little inhibition of bind-
ing was noted in nuclear extracts from cells transfected with
1 or 5 mg of pRSV–GCR-b. However, 10 mg of GCR-b
plasmid decreased GCR DNA binding by z25%, and 50
mg of plasmid blocked binding by 70%. Thus, the overex-
pression of GCR-b in HepG2 cells inhibited GCR DNA
binding activity.
Figure 4. Reversibility and cytokine induction of GCR DNA binding
abnormalities in GC-insensitive asthmatics. In these experiments, nuclear
extracts were prepared from freshly isolated PBMCs or after incubation
with culture medium or the combination of IL-2 (50 U/ml) and IL-4 (50
U/ml) for 48 h at 378C in 5% CO2. GCR DNA binding was then ana-
lyzed by EMSA as described in the Materials and Methods section.
Figure 5. Overexpression of
GCR-b reduces GCR DNA
binding affinity. HepG2 cells
grown in Dulbecco’s modified
Eagles medium containing 10%
fetal calf serum cotransfected
with the indicated amounts of
the GCR-b expression plasmid,
pRSV–GCR-b, and 5 mg
pHook-1 plasmid by CaPO4/
DNA coprecipitation. Carrier
DNA (pUC19) was added to the
precipitation reactions to bring
them to 60 mg total DNA. After
48 h, transfected cells were sepa-
rated from untransfected cells us-
ing the Capture-Tec System (Invitrogen) according to the manufacturer’s
directions. Nuclear extracts were prepared from the cells and equal
amounts of nuclear extract protein (5 mg each) were subjected to electro-
phoretic mobility shift with labeled GRE probe as described above.
Figure 6. Immunohistochemistry staining of PBMCs for expression of GCR-b. Low power magnification (3100) of cytospin preparations from PB-
MCs from (a) GC-insensitive and (b) GC-sensitive patients immunostained for GCR-b. Note the increase in the number of GCR-b–immunoreactive cells
in the GC-insensitive compared to GC-sensitive asthmatics. High power magnification (3400) of GCR-b immunoreactivity in PBMCs of (c) GC-insen-
sitive and (d) GC-sensitive patients. Representative examples of PBMCs from GC-insensitive patients showing (e) immunoglobulin isotype control for
GCR-b and (f) competitive inhibition of GCR-b immunoreactivity using preabsorption of the antibody with the GCR-b peptide.1571 Leung et al.1572 Glucocorticoid Receptor b in Glucorticoid-insensitive Asthma
These data suggest that the increased expression of
GCR-b could account for GC-insensitive asthma. To test
this hypothesis, PBMCs cytospun from seven GC-insensi-
tive asthmatics, six GC-sensitive asthmatics, and seven nor-
mal subjects were stained by immunohistochemistry tech-
nique for the expression of GCR-b. Positive staining for
GCR-b was observed on all samples stained with anti–
GCR-b (see Fig. 6, a–d), but not the immunoglobulin iso-
type control (Fig. 6 e). This staining was blocked in the
presence of purified GCR-b immunizing peptide indicat-
ing that the staining was specific for GCR-b (Fig. 6 f). As
shown in Fig. 7, GC-insensitive asthma was associated with
a significantly higher percentage of GCR-b1 cells (mean 6
SEM 5 20 6 0.8%; P ,0.001) than GC-sensitive asthmat-
ics (9 6 1%) or normal controls (6 6 1%). This abnormal
GCR-b expression in GC-insensitive PBMCs decreased
significantly (P ,0.01) toward normal after 48 h in culture
media (Fig. 8). However, incubation with combination IL-2
and IL-4 sustained this abnormality. Furthermore, combi-
nation IL-2 and IL-4 induced significantly greater (P
,0.001) GCR-b expression in normal PBMCs as com-
pared to culture medium alone or baseline values (Fig. 8).
Discussion
In the present study, we have demonstrated that patients
with GC-insensitive asthma have alterations in PBMC GCR
ligand and DNA binding affinity. These GCR binding ab-
normalities appear to be the result of increased expression
of GCR-b, a molecule which we have demonstrated to in-
hibit the action of GCs in a concentration-dependent man-
ner when its plasmid is transfected into COS-7 cells (16).
In this set of studies, we found that expression of GCR-b
was cytokine inducible in PBMCs from normal subjects,
and reversed to normal levels in GC-insensitive cells incu-
bated in the absence of cytokines.
Since IL-2 and IL-4 are T cell growth factors, the possi-
bility that preincubation with these cytokines could result
in a selective expansion of GC-insensitive cells has been
previously considered (7). However, this appears to be un-
likely since the combination of IL-2 and IL-4 did not in-
duce lymphocyte proliferation, nor was there any change
in the proportion of CD4 and CD8 cells over this 48-h
time period. Furthermore, incubation with IL-2 alone or
IL-4 alone had no effect on GCR binding. Unpublished
observations from our laboratory also indicate that GCR
alterations induced by the combination of IL-2 and IL-4
begins 1 h after their addition to PBMCs, supporting the
concept that these cytokines are not simply acting as T cell
growth factors in our cell culture system (Leung, D.Y.M.,
and S.J. Szefler, unpublished observations).
The mechanism(s) by which combination IL-2 and IL-4
enhances the expression of GCR-b is currently unknown.
GCR-a and GCR-b are generated through differential
splicing of the same GCR pre-mRNA transcript (13, 16).
Changes in GCR-a and GCR-b levels could be due to ei-
ther differences in the rates of alternative splicing, or in the
rates of RNA or protein degradation. Further studies are
required to delineate the role of these mechanisms in the
pathogenesis of GC insensitivity.
This is the first report demonstrating that cytokine-
induced expression of GCR-b may be directly involved in
the  development of GC-insensitivity in patients with
chronic asthma. These observations have important impli-
cations as the pathogenesis of other clinical conditions asso-
ciated with inflammation-induced GC insensitivity may
also involve similar mechanisms. During the past three de-
cades there has been a progressive increase in morbidity and
mortality due to chronic asthma. This increase in asthma se-
verity has been attributed to changes in our environment,
particularly with regard to allergen exposure and air pollu-
tion, both of which stimulate airway inflammation in
asthma (18, 19). Recent epidemiologic data also indicate
that early treatment with inhaled GCs to gain control of
immune activation and inflammation, is critical for success-
ful response to GCs (20, 21). Our current observation that
immune activation induces the expression of GCR-b and
thereby reduces functional responses to GCs is consistent
Figure 7. Percent of GCR-b1 cells in freshly isolated PBMCs from
GC-insensitive asthmatics versus GC-sensitive asthmatics and control sub-
jects. PBMCs were processed and stained for GCR-b immunoreactivity
as described in Materials and Methods. Cells positive for GCR-b were
scored in each preparation, by a blinded assessor, by counting 1,000 cells
and expressing them as a percentage of the total cell population.
Figure 8. Effect of combination IL-2 and IL-4 on percent GCR-b–
immunoreactive cells in PBMCs from normal subjects and GC-insensitive
asthmatics. PBMC from four normal donors and three GC-insensitive
asthma patients were analyzed for GCR-b immunoreactivity as described
in Fig. 5. PBMCs were analyzed for GCR-b immunoreactivity, freshly
isolated (time 0) and after incubation in culture medium or the combina-
tion of IL-2 and IL-4 for 48 h.1573 Leung et al.
with the concept that inflammation dampens responses to
endogenous and exogenous GCs.
Patients with GC-insensitive asthma have a tissue-specific
GC insensitivity and are therefore often subjected to con-
tinued high dose treatment with GCs, despite the onset of
serious adverse GC effects and poor clinical response to GC
therapy. The current study provides a novel marker to
identify patients with GC insensitivity who require alterna-
tive forms of antiinflammatory and immunomodulatory ther-
apy. An understanding of the mechanisms by which GCs
fail to resolve inflammation in asthma will provide impor-
tant insights into the pathogenesis of asthma, especially as it
relates to progressive deterioration, and should result in the
rational design of innovative treatment approaches.
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